international regulatory case study: the … · international regulatory case study: the...
Post on 30-Mar-2020
9 Views
Preview:
TRANSCRIPT
INTERNATIONAL REGULATORY CASE STUDY: THE COMPLEXITIES OF PRODUCT REGISTRATION
Abizer BookwalaDirector, Regulatory Affairs, GRACS BD&LGlobal Regulatory Affairs and Clinical Safety
Nov 2017
Video
3
Merck-At-A-Glance
4
• We are a global health and animal care leader with a 125-year history of working to make a difference.
• Our company is known as Merck in the United States and Canada. Everywhere else, we are known as MSD. We are approximately 69,000 employees in more than 140 countries
• We have a long history of devoting time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them.
• At Merck, we're applying our global reach, financial strength and scientific excellence to do more of what we're passionate about: improving health and improving lives.
5
Every day, 800 women die
from complications of pregnancy and
childbirth
Nearly all of these deaths are preventable
6
Maternal Mortality in the US
7
“To the world, you might be just one person, but to one person, you might be the world.”– Unknown
“Women are not dying because of diseases we cannot treat…
They are dying because societies have yet to make the decision that their lives are worth saving.”
--Dr. Mahmoud Fathalla
8
http://merckformothers.com/
Merck for Mothers is a 10-year, $500 million initiative focused on a world where no woman has to die from complications of pregnancy or childbirth
9
There are more than 50 projects in more than 30 countries around the world including India, Senegal, Uganda, the U.S., and Zambia. The concept is to test innovative models that expand women's access to affordable, quality care with the potential to be scaled and sustained.
10
11 11
12
Prevention of Postpartum Haemorrhage (PPH)
13
27%
• Postpartum haemorrhage (PPH) is the leading cause of maternal mortalityand a significant contributor to severe maternal morbidity and long termdisability worldwide*
• PPH contributes to more than 479K of maternal deaths in the developingregions from 2002-2009; 19.7% of all maternal mortality**
• The use of uterotonic drugs to prevent and treat PPH is recommended bythe World Health Organization (WHO) and national guidelines worldwide
• Oxytocin is the uterotonic drug of choice for the prevention of PPH
Background for PPH
* Alkema L, Chou D, Hogan D, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet 2016; 387: 462—74. ** Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health 2014; 2: e323—e333.
14
Limitations of Oxytocin: Current landscape
27%
• Has pervasive inconsistencies in its quality of manufacture
• Requires a consistent cold chain to maintain effectiveness
• Loses potency as it is exposed to heat
• Adds burden and complication to already fragile cold-chain infrastructure
Oxytocin is life-saving and the gold standard for preventing PPH, but it…
WHO recommends that oxytocin be refrigerated at 2-8°C to preserve its integrity. Temporary storage outside a refrigerator at a maximum of 30°C is acceptable for no more than three months.*
* USAID (2007). Prevention of Postpartum Hemorrhage: Implementing Active Management of the Third Stage of Labor (AMTSL). http://www.path.org/publications/files/MCHN_popphi_amtsl_ref_man_2of3.pdf
15
Alternative to Oxytocin - Target Product Profile
27%
1. Non-inferior efficacy, equivalent safety to oxytocin2. Heat stable long duration3. All delivery pathways (C-section & vaginal)4. IM administration5. Affordable6. Limited re-training7. Broader reach
16
27%
Carbetocin (refrigerated) in the market since 1997 Safety profile similar to oxytocin Primarily C-section indication Comparative effectiveness data suggests carbetocin may be more
efficacious than oxytocin Despite various trials & history of use, comparative effectiveness data not
yet conclusive Different study populations (CS) and route of administration (IV) Limited studies in vaginal delivery
Heat Stable version was first approved in 2015
Carbetocin
17
Maternal Mortality (2015 WHO) MfM Markets
1-19
20-99
100-299
300-499
500-999
≥1000
Population <100.000 not included in the assessment
Data not available
Not applicable
MfM Target Countries
18
27%
Merck for Mothers, Ferring Pharmaceuticals and the WHO are collaborating to develop and make accessible heat-stable Carbetocin
MSD for Mothers
Catalyst, Trial
funding
Scientific, Technical & Regulatory Expertise
Conduct, analyze phase III
trial
Update PPH treatment guidelines; EML & PQ inclusion
Country-level advocacy
Product expertise & clinical trial
supplies
Register inidentifiedcountries
Support introduction
& uptake efforts
Manufacture & access;
affordable, sustainable
price
Partnering for Success
World Health Organization
FerringPharmaceuticals
Tri-party Agreement between Merck-for-Mothers, WHO and Ferring signed in 2014
19
Attributes of the partnership
Partnering for Success
Speed to market Development of new product would not be ideal
Product cost Comparable to Oxytocin (current gold standard)
Focus on countries with greatest need Registration and availability of product in Low & Middle Income markets
Protection of partner private market revenue Partner revenue protection
Apply Merck Regulatory and Marketing expertise to support launch preparation Market access
20
Carbetocin Filing Strategy
27%
1997 - Cold chainformulation
2015 approval –Heat stable formulation
Post-Study submission - vaginal delivery
Solution for intravenous and intramuscular injection
”Name”
MAGHP
Solution for intravenous and intramuscular injection
2121
WHO TRIAL(A65870)
A. Metin Gülmezoglu, Mariana Widmer, Maternal and Perinatal Health and Preventing Unsafe Abortion
A phase III, randomized, double-blind, active controlled, multinational, multicentric, non-inferiority trial using Carbetocin room temperature stable (RTS), intramuscular (IM), for the prevention of postpartum haemorrhage
during the third stage of labour in women delivering vaginally
Australian New Zealand Clinical Trials Registry ACTRN12614000870651
22
WHO Trial
WHO sites (23)Argentina (3)Egypt (1)India (6)Kenya (1)Nigeria (2)Singapore (1)South Africa (3)Thailand (4)United Kingdom (1)Uganda (1)
10 countries – 23 centres (hospitals)30,000 women
23
Regulatory Strategy
Tri-party agreement states that Ferring should obtain registration in UK
Evaluated alternatives that may be more suitable in order to achieve the goals of the project in the target countries
Six different pathways evaluated: 1. PABAL line extension2. Duplicate Application (UK clone)3. EMA Article 584. SwissMedic Marketing Authorisation for Global Health Products (MAGHP)5. WHO route only6. Generic application
No “perfect” pathway; two most suitable are considered to be the Swiss MAGHP and the EMA article 58, both intended for supporting registrations in developing countries
24
Regulatory Strategy
MAGHP procedure is the preferred option over Article 58 procedure for the following reasons: Pros:
– MA is granted – not just an opinion like for the Article 58 procedure– CPPs and registration samples can be issued confirming launch of product
i.e. fulfil country registration requirements– Expected eligibility for WHO Pre-Qualification Collaborative Registration
Procedure (PQ CRP), which will give faster approval in 25 of the 91 Annex 2 countries, many of which are the high burden countries
Cons:– Procedure is still in the pilot phase– Slightly longer approval time than e.g. Art 58, but with access to WHO PQ
CRP, the product will get faster approval in 25 of the 91 Annex 2 countries
25
Why MAGHP?
Marketing Authorisation Global Health Products (MAGHP) is built on Swissmedic MAA procedures
– Swissmedic was collaborative during agency consultation
Collaboration between Swissmedic, WHO PQ Team and National Medicinal Regulatory Authority (NMRAs) of EAC countries (Burundi, Kenya, Rwanda, Uganda, Tanzania, South Sudan)
– Approval within 90 days of dossier submission in EAC countries.
WHO and other NMRAs may participate actively or as observer– Product is expected to be eligible for WHO PQ collaboration registration procedure (CRP),
if WHO PQT is involved in the assessment and co-listed
26
Next Steps
Once the trial ends (currently ~95% complete); 28,500 subjects are currently enrolled. LPLV expected January 2018 Assess, review and generate documents for filing, publication Update dossier/prepare filing Submit via MAGHP
– First Approval (approx 18 months post-submission)
Registration Expansion– Filing in >90 low and middle income countries, countries with highest
maternal mortality rates
Lives Saved!
27
Thank you
top related